<DOC>
	<DOCNO>NCT01609283</DOCNO>
	<brief_summary>The purpose study determine determine safety intraspinal delivery mesenchymal stem cell ( MSCs ) cerebral spinal fluid patient Amyotrophic Lateral Sclerosis ( ALS ) use dose-escalation study .</brief_summary>
	<brief_title>A Dose-escalation Safety Trial Intrathecal Autologous Mesenchymal Stem Cell Therapy Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>The primary objective study determine safety intrathecal delivery autologous mesenchymal stem cell ( MSCs ) cerebrospinal fluid ( CSF ) patient ALS use dose-escalation study . The trial include 25 adult , non-ventilator-dependent patient clinically definite amyotrophic lateral sclerosis ( ALS ) . Cells isolate adipose tissue , expand ex vivo , ~8 week , intrathecal ( IT ) autologous delivery MSCs perform . There 5 treatment group 5 patient . Groups 1 , 2 , 4 receive single dose cell . Groups 3 5 receive 2 dos cell separate 1 month . Groups complete sequentially patient enrol next treatment group least 3 patient precede group complete treatment 1 month additional observation without significant toxicity . All patient follow regular basis death minimum 2 year completion final infusion . Initial clinical follow-up weekly schedule blood , CSF magnetic resonance imaging ( MRI ) evaluation . After 1 month , patient clinical evaluation 3 month interval , earlier indicate clinical status .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>All patient must clinicallydefined ALS define World Federation Neurology criterion Age great 18 year If female , must postmenopausal hysterectomy Permanent resident citizen United States History chronic onset progressive motor weakness great one year , less two year duration Must vital capacity great 65 % predicated age , gender , body type Able comply protocol requirement , include MRI testing Can provide write informed consent Any clinically significant medical condition ( e.g. , within six month baseline , myocardial infarction , angina pectoris , and/or congestive heart failure ) , opinion investigator , would compromise safety patient . Autoimmunity , include Crohn 's disease , rheumatoid arthritis , psoriasis Malignancy include melanoma exception localize skin cancer ( evidence metastasis , significant invasion , reoccurrence within three year baseline ) . Any malignancy allow . Active systemic local infection near lumbar puncture site Other active systemic disease define laboratory abnormality Use herbal medication unapproved drug Enrolled investigational drug trial within 30 day baseline visit Kokmen Short Test Mental Status score &lt; 32 Beck 's Depression Inventory score &gt; 18 Presence tracheostomy Ventilator dependent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>